James A. Harper
Directeur/Membre du Conseil chez Baylor Regional Medical Center
Profil
Mr. James A.
Harper is a Member at The National Association of Corporate Directors, Inc. He is on the Board of Directors at Baylor Regional Medical Center.
Mr. Harper was previously employed as Independent Director by Cornerstone Therapeutics, Inc., Independent Director by Corcept Therapeutics, Inc., Chief Marketing Officer & Group Vice President by Eli Lilly & Co., and Vice President-Global Pharmaceutical Marketing by Advanced Cardiovascular Systems, Inc. He also served on the board at Phenomix Corp., Anesiva, Inc., and ZymoGenetics, Inc.
He received his undergraduate degree from Vanderbilt University and an MBA from the University of Pennsylvania.
Postes actifs de James A. Harper
| Sociétés | Poste | Début |
|---|---|---|
| Baylor Regional Medical Center | Directeur/Membre du Conseil | 09/05/2012 |
National Association of Corporate Directors (Virginia)
 National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Corporate Officer/Principal | 01/03/2006 |
Anciens postes connus de James A. Harper
| Sociétés | Poste | Fin |
|---|---|---|
| ISLET SCIENCES INC | Directeur des opérations | 19/10/2015 |
| CORNERSTONE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/02/2014 |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Directeur/Membre du Conseil | 28/10/2010 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Directeur/Membre du Conseil | 08/10/2010 |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | 15/12/2008 |
Formation de James A. Harper
| Vanderbilt University | Undergraduate Degree |
| University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CORCEPT THERAPEUTICS INCORPORATED | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 8 |
|---|---|
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Abbott Cardiovascular Systems, Inc.
 Abbott Cardiovascular Systems, Inc. Medical SpecialtiesHealth Technology Abbott Cardiovascular Systems, Inc. manufactures medical devices. It also makes cardiac and peripheral vascular repair surgical systems. The company was founded in 1978 and is headquartered in Santa Clara, CA. | Health Technology |
Anesiva, Inc.
Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Anesiva, Inc. develops and markets therapeutic drugs. Anesiva is a biopharmaceutical company focused on the development and commercialization of novel pharmaceutical products for pain management. The firm was founded in 1999 and is headquartered in San Francisco, CA. | Health Technology |
Cornerstone Therapeutics, Inc.
 Cornerstone Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC. | Health Technology |
| Baylor Regional Medical Center | |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | Commercial Services |
Islet Sciences, Inc.
 Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA. | Commercial Services |
